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Considerable controversy exists among experts in pulmonary
vascular biology regarding endothelin A (ETA) and endothelin B
(ETB) selectivity of endothelin receptor antagonist (ERA) drugs used
to treat pulmonary arterial hypertension (PAH). Some experts
believe that dual ETA/ETB blockade is superior due to the effects
of ETB on vascular ﬁbrosis, while others have shown evidence for
superiority in endothelin-1 clearance with ETA-selective drugs.
There are also mixed opinions as to the degree of relative ETA/ETB
selectivity conferred by existing ERAs currently used in clinical
practice. This lecture will present some of the existing basic science
and clinical data that address ETA and/or ETB selectivity, and discuss
its relevance to clinical practice.
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Ren2-transgenic rats (TGR) with inserted Ren-2 murine gene are
a model of angiotensin II-dependent hypertension (with endogenous
activation of the renin–angiotensin system) which bear a salt-
sensitive component. Their hypertension develops early in life
(at 4–5 weeks of age). While heterozygous animals survive hyper-
tension development, hypertension in the homozygous strain is
very severe and leads to high mortality. Thus, heterozygous TGR
provide a more suitable model of hypertension regarding clinical
studies. Our studies with endothelin (ET) receptor blockade were
performed in young (4-weeks-old) rats (prevention study) and adult
(50-days-old) rats (regression study) fed either normal (0.45%
NaCl) or high-salt diet (2% NaCl). Bosentan or atrasentan were given
until day 90 of age. High-salt diet was applied not only to induce the
transition from benign to malignant phase of hypertension but also
to activate ET system. Prevention study in homozygous TGR has
demonstrated that both nonselective blockade with bosentan and
selective blockade with atrasentan decreased mortality. Proteinuria,
glomerulosclerosis, cardiac hypertrophy, as well as left ventricular
ET-1 content were partly reduced by bosentan and to a greater
extent by atrasentan. However, only atrasentan exerted antihyper-
tensive effects (30 mm Hg). In the regression study (started at time
when hypertension has already been developed) atrasentan tran-
siently decreased blood pressure (BP) in homozygous TGR. However,
there was no difference in BP between different groups at the end
of the study. Interestingly, atrasentan had profound effects on
survival. This was accompanied by substantially reduced glomerular
podocyte injury, which strongly correlated with the survival. This
effect was thus independent of BP. Prevention study in heterozygous
TGR conﬁrmed previous results obtained in homozygous animals,
i.e. similar effects of nonselective and selective ET blockade on the
improvement of survival, cardiac hypertrophy, glomerulosclerosis
and ET-1 levels with superior effects of selective ETA blockade on
proteinuria and hypertension. In the regression study in heterozygous
TGR, beneﬁcial effects of ETA blockade were substantiated by the
ﬁndings of restoration of podocyte structure and reversal of podocyte
phenotype changes represented by the expression of CD 10, desmin
and vimentin. In the recent study we have analyzed the effects
of ETA blockade on the distinct vasoactive systems contributing to
BP maintenance. We have found that BP component dependent on
calcium entry through L-type voltage-dependent calcium (L-VDCC)
channels was markedly decreased by atrasentan treatment. In
addition, vasodilatation through NO, endogenous prostanoids and
BKCa channels (mediated by ETB receptors) was strongly reduced in
atrasentan-treated TGR. Our experiments have demonstrated that BP
lowering effect of atrasentan ismainly due to the reduced Ca2+ inﬂux
via L-VDCC channels. In conclusion, our results have shown that
selective ETA blockade is superior in many aspects to the nonselective
ETA/ETB blockade, this effect being dependent on the preservation of
the ﬁltration barrier of the kidney.
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